Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 19, 2009 - Issue 6
Submit an article Journal homepage
1,386
Views
80
CrossRef citations to date
0
Altmetric
Reviews

Histone acetyltransferase inhibitors and preclinical studies

Fabio Manzo Seconda Università degli Studi di Napoli, Dipartimento di Patologia generale, Vico L. De Crecchio 7, 80138, Napoli, IT +39 081 566 7569; +39 081 224 4840; [email protected]
,
Francesco Paolo Tambaro Seconda Università degli Studi di Napoli, Dipartimento di Patologia generale, Vico L. De Crecchio 7, 80138, Napoli, IT +39 081 566 7569; +39 081 224 4840; [email protected]; University of Houston, MD Anderson Cancer Center, Texas, USA
,
Antonello Mai Sapienza Università di Roma, Istituto Pasteur, Fondazione Cenci-Bolognetti, Dipartimento di Chimica e Tecnologie del Farmaco, P.le A. Moro 5, 00185 Roma, IT
&
Lucia Altucci Seconda Università degli Studi di Napoli, Dipartimento di Patologia generale, Vico L. De Crecchio 7, 80138, Napoli, IT +39 081 566 7569; +39 081 224 4840; [email protected]
Pages 761-774 | Published online: 26 Apr 2009

Bibliography

  • Altucci L, Stunnenberg HG. Time for epigenetics. Int J Biochem Cell Biol 2009;41(1):2-3
  • Peters AH, Mermoud JE, O'Carroll D, et al. Histone H3 lysine 9 methylation is an epigenetic imprint of facultative heterochromatin. Nat Genet 2002;30(1):77-80
  • Schotta G, Lachner M, Peters AH, Jenuwein T. The indexing potential of histone lysine methylation. Novartis Found Symp 2004;259:22-37; discussion -47, 163-9
  • Brown CE, Lechner T, Howe L, Workman JL. The many HATs of transcription coactivators. Trends Biochem Sci 2000;25(1):15-9
  • Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5(9):769-84
  • Kimura A, Matsubara K, Horikoshi M. A decade of histone acetylation: marking eukaryotic chromosomes with specific codes. J Biochem 2005;138(6):647-62
  • Grant PA, Duggan L, Cote J, et al. Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. Genes Dev 1997;11(13):1640-50
  • Pray-Grant MG, Daniel JA, Schieltz D, et al. Chd1 chromodomain links histone H3 methylation with SAGA- and SLIK-dependent acetylation. Nature 2005;433(7024):434-8
  • Martin DG, Grimes DE, Baetz K, Howe L. Methylation of histone H3 mediates the association of the NuA3 histone acetyltransferase with chromatin. Mol Cell Biol 2006;26(8):3018-28
  • Wittschieben BO, Otero G, de Bizemont T, et al. A novel histone acetyltransferase is an integral subunit of elongating RNA polymerase II holoenzyme. Mol Cell 1999;4(1):123-8
  • Dhalluin C, Carlson JE, Zeng L, et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 1999;399(6735):491-6
  • Joshi AA, Struhl K. Eaf3 chromodomain interaction with methylated H3-K36 links histone deacetylation to Pol II elongation. Mol Cell 2005;20(6):971-8
  • Couture JF, Collazo E, Trievel RC. Molecular recognition of histone H3 by the WD40 protein WDR5. Nat Struct Mol Biol 2006;13(8):698-703
  • Wysocka J, Swigut T, Milne TA, et al. WDR5 associates with histone H3 methylated at K4 and is essential for H3 K4 methylation and vertebrate development. Cell 2005;121(6):859-72
  • Fraga MF, Ballestar E, Villar-Garea A, et al. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 2005;37(4):391-400
  • Shogren-Knaak M, Ishii H, Sun JM, et al. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006;311(5762):844-7
  • Akhtar A, Becker PB. Activation of transcription through histone H4 acetylation by MOF, an acetyltransferase essential for dosage compensation in Drosophila. Mol Cell 2000;5(2):367-75
  • Smith ER, Cayrou C, Huang R, et al. A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol 2005;25(21):9175-88
  • Meijsing SH, Ehrenhofer-Murray AE. The silencing complex SAS-I links histone acetylation to the assembly of repressed chromatin by CAF-I and Asf1 in Saccharomyces cerevisiae. Genes Dev 2001;15(23):3169-82
  • Osada S, Sutton A, Muster N, et al. The yeast SAS (something about silencing) protein complex contains a MYST-type putative acetyltransferase and functions with chromatin assembly factor ASF1. Genes Dev 2001;15(23):3155-68
  • Shia WJ, Osada S, Florens L, et al. Characterization of the yeast trimeric-SAS acetyltransferase complex. J Biol Chem 2005;280(12):11987-94
  • Suka N, Luo K, Grunstein M. Sir2p and Sas2p opposingly regulate acetylation of yeast histone H4 lysine16 and spreading of heterochromatin. Nat Genet 2002;32(3):378-83
  • Kouzarides T. Acetylation: a regulatory modification to rival phosphorylation? Embo J 2000;19(6):1176-9
  • Frank SR, Schroeder M, Fernandez P, et al. Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev 2001;15(16):2069-82
  • Kenneth NS, Ramsbottom BA, Gomez-Roman N, et al. TRRAP and GCN5 are used by c-Myc to activate RNA polymerase III transcription. Proc Natl Acad Sci USA 2007;104(38):14917-22
  • Martinez-Balbas MA, Bauer UM, Nielsen SJ, et al. Regulation of E2F1 activity by acetylation. EMBO J 2000;19(4):662-71
  • Marzio G, Wagener C, Gutierrez MI, et al. E2F family members are differentially regulated by reversible acetylation. J Biol Chem 2000;275(15):10887-92
  • Lang SE, McMahon SB, Cole MD, Hearing P. E2F transcriptional activation requires TRRAP and GCN5 cofactors. J Biol Chem 2001;276(35):32627-34
  • Taubert S, Gorrini C, Frank SR, et al. E2F-dependent histone acetylation and recruitment of the Tip60 acetyltransferase complex to chromatin in late G1. Mol Cell Biol 2004;24(10):4546-56
  • Oishi H, Kitagawa H, Wada O, et al. An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification. J Biol Chem 2006;281(1):20-6
  • Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004;23(24):4225-31
  • Poux AN, Cebrat M, Kim CM, et al. Structure of the GCN5 histone acetyltransferase bound to a bisubstrate inhibitor. Proc Natl Acad Sci USA 2002;99(22):14065-70
  • Clements A, Marmorstein R. Insights into structure and function of GCN5/PCAF and yEsa 1 histone acetyltransferase domains. Methods Enzymol 2003;371:545-64
  • Clements A, Rojas JR, Trievel RC, et al. Crystal structure of the histone acetyltransferase domain of the human PCAF transcriptional regulator bound to coenzyme A. EMBO J 1999;18(13):3521-32
  • Liu X, Wang L, Zhao K, et al. The structural basis of protein acetylation by the p300/CBP transcriptional coactivator. Nature 2008;451(7180):846-50
  • Varier RA, Swaminathan V, Balasubramanyam K, Kundu TK. Implications of small molecule activators and inhibitors of histone acetyltransferases in chromatin therapy. Biochem Pharmacol 2004;68(6):1215-20
  • Balasubramanyam K, Altaf M, Varier RA, et al. Polyisoprenylated benzophenone, garcinol, a natural histone acetyltransferase inhibitor, represses chromatin transcription and alters global gene expression. J Biol Chem 2004;279(32):33716-26
  • Morinobu A, Biao W, Tanaka S, et al. (-)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis Rheum 2008;58(7):2012-8
  • Balasubramanyam K, Varier RA, Altaf M, et al. Curcumin, a novel p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. J Biol Chem 2004;279(49):51163-71
  • Marcu MG, Jung YJ, Lee S, et al. Curcumin is an inhibitor of p300 histone acetylatransferase. Med Chem 2006;2(2):169-74
  • Biel M, Wascholowski V, Giannis A. Epigenetics–an epicenter of gene regulation: histones and histone-modifying enzymes. Angew Chem Int Ed Engl 2005;44(21):3186-216
  • Stimson L, Rowlands MG, Newbatt YM, et al. Isothiazolones as inhibitors of PCAF and p300 histone acetyltransferase activity. Mol Cancer Ther 2005;4(10):1521-32
  • Mantelingu K, Reddy BA, Swaminathan V, et al. Specific inhibition of p300-HAT alters global gene expression and represses HIV replication. Chem Biol 2007;14(6):645-57
  • Ornaghi P, Rotili D, Sbardella G, et al. A novel Gcn5p inhibitor represses cell growth, gene transcription and histone acetylation in budding yeast. Biochem Pharmacol 2005;70(6):911-7
  • Mai ARD, Ornaghi P, Tosi F, et al. Identification of small molecules inhibitors of GCN5 histone acetyltransferase activity. J Med Chem 2006;8:24-37
  • Mai A, Rotili D, Tarantino D, et al. Small-molecule inhibitors of histone acetyltransferase activity: identification and biological properties. J Med Chem 2006;49(23):6897-907
  • Smith AT, Livingston MR, Mai A, et al. Quinoline derivative MC1626, a putative GCN5 histone acetyltransferase (HAT) inhibitor, exhibits HAT-independent activity against Toxoplasma gondii. Antimicrob Agents Chemother 2007;51(3):1109-11
  • Mai ARD, Tarantino D, Nebbioso A, et al. Identification of 4-hydroxyquinolines inhibitors of p300/CBP histone acetyltransferases. Bioorg Med Chem Lett 2009;19(4):1132-5
  • Mai A, Massa S, Rotili D, et al. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 2005;25(3):261-309
  • Miller TA, Witter DJ, Belvedere S. Histone deacetylase inhibitors. J Med Chem 2003;46(24):5097-116
  • Mai A, Massa S, Rotili D, et al. Exploring the connection unit in the HDAC inhibitor pharmacophore model: novel uracil-based hydroxamates. Bioorg Med Chem Lett 2005;15(21):4656-61
  • Nebbioso A, Clarke N, Voltz E, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005;11(1):77-84
  • Manzo F, Nebbioso A, Miceli M, et al. TNF-related apoptosis-inducing ligand: Signalling of a ‘smart’ molecule. Int J Biochem Cell Biol 2007;41(3):460-6
  • Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 2009;41(1):199-213
  • LK-M, inventor. Composition for prevention and/or treatment of cancer. US2008260695; 2008
  • RMIRA, inventor. Turmeric compositions and methods for the preparation there of. WO2008096343A1; 2008
  • DTM, inventor. Intranasally administering curcumin in a bolus of helium gas to treat alzheimer's disease. WO2008131059A2; 2008
  • Lim GP, Chu T, Yang F, et al. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001;21(21):8370-7
  • Frautschy SA, Hu W, Kim P, et al. Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology. Neurobiol Aging 2001;22(6):993-1005
  • SJPUDMC, inventor. Curcumin analogs with anti-tumor and anti-angiogenic properties. US2008234320A1; 2008
  • Binion DG, Otterson MF, Rafiee P. Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut 2008;57(11):1509-17
  • Funk JL, Oyarzo JN, Frye JB, et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. J Nat Prod 2006;69(3):351-5
  • Jacob A, Wu R, Zhou M, Wang P. Mechanism of the Anti-inflammatory Effect of Curcumin: PPAR-gamma Activation. PPAR Res 2007;2007:89369
  • Neekv, inventor. Art of preparing derivatives of anacardic acid. US2251547A; 1941
  • Shigehiro TTK, inventor. Carcinogenesis prophylactic. JP2000355536A; 2000
  • Yukihiko KSI, inventor. Antiinflammatory agent. JP2000351728A; 2000
  • Shishodia S, Amin HM, Lai R, Aggarwal BB. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 2005;70(5):700-13
  • Shishodia S, Chaturvedi MM, Aggarwal BB. Role of curcumin in cancer therapy. Curr Probl Cancer 2007;31(4):243-305
  • Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res 2003;23(1A):363-98
  • Huang MT, Smart RC, Wong CQ, Conney AH. Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate. Cancer Res 1988;48(21):5941-6
  • Huang HC, Jan TR, Yeh SF. Inhibitory effect of curcumin, an anti-inflammatory agent, on vascular smooth muscle cell proliferation. Eur J Pharmacol 1992;221(2-3):381-4
  • Sun Y, Jiang X, Chen S, Price BD. Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett 2006;580(18):4353-6
  • Trevisan MT, Pfundstein B, Haubner R, et al. Characterization of alkyl phenols in cashew (Anacardium occidentale) products and assay of their antioxidant capacity. Food Chem Toxicol 2006;44(2):188-97
  • Singh S, Aggarwal BB. Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem 1995;270(42):24995-5000
  • Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol 1999;163(6):3474-83
  • Plummer SM, Holloway KA, Manson MM, et al. Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-kappaB activation via the NIK/IKK signalling complex. Oncogene 1999;18(44):6013-20
  • Philip S, Kundu GC. Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. J Biol Chem 2003;278(16):14487-97
  • Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005;104(4):879-90
  • Chen X, Hasuma T, Yano Y, et al. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin. Anticancer Res 1997;17(4A):2555-64
  • Reddy S, Aggarwal BB. Curcumin is a non-competitive and selective inhibitor of phosphorylase kinase. FEBS Lett 1994;341(1):19-22
  • Kim KH, Park HY, Nam JH, et al. The inhibitory effect of curcumin on the growth of human colon cancer cells (HT-29, WiDr) in vitro. Korean J Gastroenterol 2005;45(4):277-84
  • Fang J, Lu J, Holmgren A. Thioredoxin reductase is irreversibly modified by curcumin: a novel molecular mechanism for its anticancer activity. J Biol Chem 2005;280(26):25284-90
  • Youn HS, Saitoh SI, Miyake K, Hwang DH. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. Biochem Pharmacol 2006;72(1):62-9
  • Bustanji Y, Taha MO, Almasri IM, et al. Inhibition of glycogen synthase kinase by curcumin: investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. J Enzyme Inhib Med Chem 2008;7:1
  • Santel T, Pflug G, Hemdan NY, et al. Curcumin inhibits glyoxalase 1: a possible link to its anti-inflammatory and anti-tumor activity. PLoS ONE 2008;3(10):e3508
  • NTP Toxicology and Carcinogenesis Studies of Turmeric Oleoresin (CAS No. 8024-37-1) (Major Component 79%-85% Curcumin, CAS No. 458-37-7) in F344/N Rats and B6C3F1 Mice (Feed Studies). Natl Toxicol Program Tech Rep Ser 1993;427:1-275
  • Lopez-Lazaro M, Willmore E, Austin CA. Cells lacking DNA topoisomerase II beta are resistant to genistein. J Nat Prod 2007;70(5):763-7
  • Lopez-Lazaro M, Willmore E, Jobson A, et al. Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells. J Nat Prod 2007;70(12):1884-8
  • Martin-Cordero C, Lopez-Lazaro M, Galvez M, Ayuso MJ. Curcumin as a DNA topoisomerase II poison. J Enzyme Inhib Med Chem 2003;18(6):505-9
  • Moos PJ, Edes K, Mullally JE, Fitzpatrick FA. Curcumin impairs tumor suppressor p53 function in colon cancer cells. Carcinogenesis 2004;25(9):1611-7
  • Kishimoto M, Kohno T, Okudela K, et al. Mutations and deletions of the CBP gene in human lung cancer. Clin Cancer Res 2005;11(2 Pt 1):512-9
  • Yang DI, Yeh CH, Chen S, et al. Neutral sphingomyelinase activation in endothelial and glial cell death induced by amyloid beta-peptide. Neurobiol Dis 2004;17(1):99-107
  • Wu J, Xie N, Wu Z, et al. Bisubstrate Inhibitors of the MYST HATs Esa1 and Tip60. Bioorg Med Chem 2008

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.